Pfizer New Drug For Alopecia Areata

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with.

• Aug 05, 2021Pfizer has reported positive top-line data from the Phase IIb/III ALLEGRO clinical trial of its drug, ritlecitinib, in alopecia areata patients. Alopecia areata is an autoimmune.

• Jun 14, 2022Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit. Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia.

• Apr 02, 2022Etrasimod, the drug developed, is an oral drug to be used once daily. Etrasimod can be used for patients suffering from immune-inflammatory diseases such as Chron’s Disease,.